REIG JOFRE is a pharmaceutical company founded with the firm conviction of universalizing health, bringing the most basic to the most innovative solutions to people worldwide. REIG JOFRE is the key step between research and curing. To provide pioneering and high-impact solutions, they have cutting-edge technological production, continuously collaborate with other innovative companies, researchers, and startups, and constantly invest in R&D+i.
Since 1929, they have been researching, developing, manufacturing, and marketing pharmaceutical products essential for people’s health, under three main areas: Pharmaceutical Technologies, specializing in sterile injectables and lyophilized products, and penicillin-derived antibiotics; Specialty Pharmacare in Dermatology and Osteoarticular, mainly; and Consumer Healthcare, with consumer-directed products under the Forté Pharma brand, primarily in France, Belgium, Spain, and Portugal, and other OTC products.
REIG JOFRE is listed on the continuous market of the Spanish stock exchange under the code RJF and is the fifth-largest Spanish pharmaceutical laboratory by revenue listed on the stock market. Its track record supports its adaptability and industrialization experience to meet the global health needs of today and tomorrow.
REIG JOFRE has four development and production centers in Europe (2 in Toledo, 1 in Barcelona, and 1 in Malmö), its own teams in Spain, France, Portugal, Belgium, Sweden, the United Kingdom, and Poland, and has more than 1,300 employees. It has an extensive network of commercial partners in over 70 countries. The company closed 2023 with a turnover of 316 million euros in sales (+17% vs. 2022) and an EBITDA of 35 million euros (+15% vs. 2022).
Member of:
